https://doi.org/10.48047/AFJBS.6.Si3.2024.1760-1776

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Mucus-Penetrating Nanoparticles for Therapeutic Drug Delivery: Recent advances and future perspectives

Harsh Rastogi[1], Ankur Gupta[2], Siddharth Dhaka[3], Anupama Patel[4], Gunjan Sharma[5], Neeraj Madhuria[6], Vasundhara Saxena[7*]

[1]Assistant Professor, Department of Pharmaceutics, Dr K.N. Modi Institute of Pharmaceutical Education and Research Modinagar Ghaziabad Uttar Pradesh

[2]Assistant Professor, Department of Quality Assurance, Venkateshwara Group of Institution, Meerut

[3]Assistant Professor, Department of Pharmaceutics, Dr KN Modi Institute of Pharmaceutical Education and Research Modinagar, Ghaziabad UP

[4]Assistant professor Venkateshwara College of pharmacy, Meerut

[5]Assistant professor, Sharda School of pharmacy, Agra

[6]Assistant professor, Anand College of pharmacy, Agra

[*7]Associate Professor, Anand College of Pharmacy, Agra

Article Info

Volume 6, Issue 6, June 2024

Received: 17 April 2024

Accepted: 27 May 2024

Published: 20 June 2024

doi: 10.48047/AFJBS.6.Si3.2024.1760-1776

ABSTRACT:

Mucus, a viscoelastic and adhesive gel, forms a significant barrier to the efficient delivery of therapeutic particles to mucosal surfaces. This barrier hinders the penetration of nanoparticles, leading to rapid clearance and reduced efficacy of treatments. To overcome this challenge, researchers have developed mucus-penetrating nanoparticles (MPPs) that can traverse the mucus layer efficiently. These particles are designed to avoid adhesion to mucin fibers and are small enough to navigate the dense fiber mesh. Recent studies have demonstrated that MPPs can rapidly traverse physiological human mucus with diffusivities comparable to those in pure water. This breakthrough offers the prospect of sustained drug delivery at mucosal surfaces, potentially improving the efficacy and reducing side effects of a wide range of therapeutics. The development of MPPs loaded with nucleic acids may also enhance the efficacy of gene therapies. This review highlights the mechanisms by which mucus hinders particle penetration and discusses recent advancements in the design and development of MPPs, which hold promise for improved mucosal drug delivery.

Keywords: Mucus-penetrating nanoparticles, mucosal drug delivery, Nanoparticle transport, Mucin fibers, Gene therapy.

I. Introduction

Mucosal drug delivery is an essential method for administering therapeutic agents directly to mucosal tissues, including the gastrointestinal, respiratory, urogenital tracts, and ocular surfaces [1]. These sites offer several advantages for drug administration, such as large surface areas, rich vascularization, and the potential for both local and systemic drug delivery[2]. Local delivery is particularly beneficial in treating diseases that affect specific mucosal sites, such as inflammatory bowel disease (IBD), asthma, or vaginal infections [3]. Systemic delivery via mucosal routes can be advantageous due to the potential for avoiding the first-pass metabolism in the liver, which can degrade drugs before they reach systemic circulation [4]. Applications of mucosal drug delivery are diverse and include vaccines, where mucosal immunization can provide both systemic and mucosal immunity; treatment of chronic conditions like diabetes through pulmonary insulin delivery; and administering contraceptives via vaginal rings [5]. Moreover, the non-invasive nature of mucosal drug delivery improves patient compliance compared to injectable routes, making it a preferred choice for long-term therapies. Despite its advantages, mucosal drug delivery faces significant challenges [6]. The primary barrier is the mucus layer itself, which is a viscoelastic and gel-like substance covering mucosal surfaces. Mucus acts as a protective barrier, trapping and expelling foreign particles, including pathogens and drug carriers. This barrier function is due to the dense network of mucin glycoproteins, which can hinder the diffusion of drugs and nanoparticles [7]. Additionally, the rapid turnover of mucus can lead to the quick clearance of drug carriers, reducing the residence time and, consequently, the drug absorption [8]. Enzymatic degradation within the mucosal environment also poses a threat to the stability of drugs, particularly peptides and proteins. Overcoming these challenges requires innovative strategies to enhance drug penetration and retention at the mucosal surface [9].

Nanoparticles have revolutionized drug delivery due to their unique properties, such as small size, large surface area, and the ability to modify their surface characteristics [10]. These properties enable nanoparticles to encapsulate drugs, protecting them from degradation and enhancing their stability [11]. Nanoparticles can be engineered to control the release of drugs over an extended period, improving therapeutic outcomes and reducing dosing frequency [12]. Moreover, nanoparticles can be functionalized with targeting ligands, allowing them to selectively bind to specific cells or tissues [13]. This targeted delivery minimizes systemic side effects and maximizes the therapeutic effect at the desired site [14]. The versatility in designing nanoparticles makes them suitable for delivering a wide range of therapeutics, including small molecules, proteins, peptides, and nucleic acids. Nanoparticles can also enhance the absorption of poorly soluble drugs by increasing their apparent solubility and promoting uptake through endocytosis or transcytosis [15]. Furthermore, they can be designed to release their payload in response to specific stimuli present in the mucosal environment, such as pH changes or enzymatic activity, ensuring that the drug is released at the optimal site and time for maximum therapeutic effect [16]. Mucus-penetrating nanoparticles (MPNs) represent a specialized class of nanoparticles designed to overcome the barrier properties of mucus. Unlike conventional nanoparticles that may be trapped and cleared by the mucus, MPNs are engineered to rapidly diffuse through the mucus layer. This ability is primarily achieved through surface modifications that minimize adhesive interactions with mucin fibers [17].

MPNs are typically small, often in the range of tens to a few hundred nanometers, and have a neutral or slightly negative surface charge to reduce electrostatic interactions with the negatively charged mucus. Surface coatings, such as polyethylene glycol (PEG), are commonly used to create a "stealth" layer that prevents mucoadhesion and facilitates unhindered movement through the mucus [18].

II. Composition and Design of Mucus-Penetrating Nanoparticles

The design and composition of mucus-penetrating nanoparticles (MPNs) are crucial for their ability to traverse the mucus barrier and deliver therapeutic agents effectively to the underlying tissues. The success of MPNs hinges on the careful selection of materials and sophisticated design strategies that enhance their stability, biocompatibility, and penetration capabilities [2, 6, and 19].

A. Materials Used in MPNs

1. Polymers

Polymers are the most commonly used materials in the formulation of MPNs due to their versatility, biocompatibility, and ease of modification. Polymers like polyethylene glycol (PEG), poly (lactic-co-glycolic acid) (PLGA), and chitosan are frequently employed.

Polyethylene Glycol (PEG): PEG is renowned for its ability to resist protein adsorption and avoid immune recognition, making it an ideal candidate for creating the stealth characteristics needed for mucus penetration. The hydrophilic nature of PEG helps in reducing mucoadhesion, facilitating better diffusion through the mucus [20].

Poly (Lactic-Co-Glycolic Acid) (PLGA): PLGA is a biodegradable polymer that can be used to create nanoparticles with controlled release properties. Its degradation products, lactic acid and glycolic acid, are biocompatible and safely metabolized by the body [21].

Chitosan: Chitosan, a naturally occurring polymer derived from chitin, has mucoadhesive properties that can be advantageous in certain contexts. However, for MPNs, it is often modified to reduce its adhesiveness to mucin fibers, enhancing its mucus-penetrating capabilities [22].

2. Lipids

Lipid-based nanoparticles, such as liposomes and solid lipid nanoparticles (SLNs), represent versatile platforms with unique advantages for mucosal drug delivery. Liposomes are spherical vesicles composed of lipid bilayers that can encapsulate a wide range of drugs, including both hydrophilic and hydrophobic compounds [23]. They can be further modified by PEGylation to improve their mucus-penetrating ability and extend their circulation time in the body. Solid lipid nanoparticles (SLNs), on the other hand, offer a solid matrix composed of lipids that can also encapsulate drugs effectively [3]. SLNs combine the benefits of liposomes' drug encapsulation capacity with the stability and controlled release characteristics typical of polymeric nanoparticles [24]. These nanoparticles can be engineered to enhance mucus penetration, facilitating efficient drug delivery through mucosal barriers while providing sustained release profiles that contribute to improved therapeutic outcomes [11,7]. The biocompatibility and flexibility of lipid-based nanoparticles make them promising candidates for delivering therapeutics across various mucosal surfaces, addressing the challenges associated with mucosal drug delivery and expanding the potential applications in clinical settings [25].

3. Other Materials

In addition to polymers and lipids, mucus-penetrating nanoparticles (MPNs) explore the use of other materials such as dendrimers, inorganic nanoparticles like silica and gold, and hybrid nanoparticles that combine organic and inorganic components [26]. Dendrimers, characterized by their highly branched, tree-like structures, offer multiple functional groups for drug attachment and surface modification, thereby enhancing their affinity for biological

environments and improving targeted drug delivery [27]. Inorganic nanoparticles such as silica and gold possess unique optical and magnetic properties that are advantageous for both diagnostic imaging and therapeutic applications. These nanoparticles can be functionalized on their surfaces to enhance mucus penetration and biocompatibility, enabling efficient delivery of drugs across mucosal barriers [28]. Hybrid nanoparticles, integrating organic and inorganic components, leverage the strengths of both materials to achieve synergistic effects in drug encapsulation, stability, and targeting capabilities. By exploring diverse material options, MPNs continue to advance in their ability to overcome biological barriers and optimize drug delivery strategies for enhanced therapeutic outcomes in various medical applications [29].



Figure 1: Schematic illustrating mucus-penetrating nanoparticles.

B. Surface Modification Techniques

1. PEGylation

PEGylation, the process of attaching polyethylene glycol (PEG) chains to nanoparticles, is a cornerstone technique in the design of mucus-penetrating nanoparticles (MPNs) [30]. PEGylation confers several critical properties: firstly, it reduces protein adsorption by creating a hydrophilic shield around nanoparticles, thereby preventing immune recognition and clearance caused by protein corona formation [31]. Secondly, the hydrophilic and flexible nature of PEG enhances mucus penetration, enabling nanoparticles to move more freely through the dense mucus layer without becoming entangled in mucin fibers [32]. Finally, PEGylation prolongs circulation time by evading uptake by the mononuclear phagocyte system (MPS), allowing PEGylated nanoparticles to persist in circulation longer and enhancing their chances of reaching and delivering therapeutic payloads to target tissues effectively [33]. These attributes underscore the pivotal role of PEGylation in enhancing the biocompatibility, mucus-penetrating ability, and systemic circulation of MPNs, thereby optimizing their potential for targeted drug delivery applications across various mucosal surfaces [34].

2. Ligand Attachment

In addition to attaching specific ligands to nanoparticles, which can include small molecules, peptides, antibodies, or aptamers designed to bind to receptors on mucosal surfaces or epithelial cells, charge modulation of nanoparticle surfaces is another critical strategy to enhance their ability to target and penetrate mucus barriers [35]. Ligands facilitate targeted delivery by directing nanoparticles to specific cells or tissues, thereby increasing the concentration of therapeutic agents at the desired site. They can also improve penetration through active transport mechanisms across mucus and epithelial barriers, enhancing the efficiency of drug delivery [36]. Surface charge plays a pivotal role in nanoparticle interactions with mucus,

which is typically negatively charged due to sialic acid residues on mucins. Adjusting the surface charge to neutral or slightly negative can reduce electrostatic interactions with mucus, facilitating deeper penetration. Advanced nanoparticles are designed with dynamic charge modulation capabilities that enable them to adapt to the mucosal environment [37]. Initially, these nanoparticles can penetrate mucus more effectively due to their optimized surface charge, and then adjust to interact more efficiently with target cells. This dual strategy of ligand attachment and charge modulation underscores the versatility and potential of nanoparticles in overcoming biological barriers for enhanced drug delivery in mucosal applications [38].

C. Core-Shell Structures and Encapsulation Strategies

1. Drug Loading Techniques

The core-shell structure of nanoparticles serves as a versatile platform for drug encapsulation, ensuring both stability and controlled release. Various techniques are employed to load drugs into mucus-penetrating nanoparticles (MPNs) [39]. Hydrophilic drugs can be encapsulated within the aqueous core of nanoparticles such as liposomes, while hydrophobic drugs can be embedded within the lipid bilayer or polymer matrix that forms the shell of the nanoparticle. Surface adsorption represents a simpler method where drugs are attached onto the surface of nanoparticles, although this approach may lead to faster release rates [40]. Alternatively, intercalation techniques involve layer-by-layer assembly, allowing drugs to be inserted between alternating layers of materials. This method offers precise control over drug loading and release kinetics, ensuring optimal therapeutic efficacy [41]. Each loading technique offers distinct advantages depending on the specific characteristics of the drug and the desired release profile, highlighting the versatility of core-shell nanoparticles in facilitating efficient drug delivery across mucosal barriers [42].

2. Stability Considerations

Stability is a crucial consideration in the design of mucus-penetrating nanoparticles (MPNs), ensuring their effectiveness throughout storage, transit through mucus layers, and controlled release of therapeutic pay loads [43]. Chemical stability is paramount, necessitating that the materials comprising MPNs resist degradation when exposed to mucus and bodily fluids. This resilience ensures the nanoparticles maintain their structural integrity and drug encapsulation capabilities until they reach their target site [44]. Physical stability is equally vital to prevent nanoparticles from aggregating or undergoing undesired phase transitions, which could compromise their ability to penetrate mucus effectively. Controlled release mechanisms are engineered to regulate the release profile of encapsulated drugs, ensuring they are delivered at the optimal rate and location within the body [45]. This precision not only maximizes therapeutic efficacy by maintaining therapeutic concentrations over time but also minimizes potential side effects associated with fluctuating drug levels. Together, these aspects of stability in MPN design are critical for enhancing drug delivery efficiency across mucosal barriers and advancing their application in targeted therapeutic interventions [46].

III. Mechanisms of Mucus Penetration

Understanding the mechanisms by which mucus-penetrating nanoparticles (MPNs) navigate the complex mucus barrier is crucial for optimizing their design and enhancing their efficacy in drug delivery [47].

A. Interaction with Mucus Components

1. Mucins

Mucins are large, glycosylated proteins that form the structural backbone of mucus, creating a dense, mesh-like network. The interaction between MPNs and mucins is a key factor in

determining the penetration capabilities of the nanoparticles. Mucins possess numerous glycosylated domains that can trap and bind foreign particles through various interactions, including hydrogen bonding, electrostatic interactions, and hydrophobic forces [48]. For MPNs to effectively navigate through this network, they must minimize these interactions. This is often achieved through surface modifications, such as PEG ylation, which imparts a hydrophilic and neutral surface to the nanoparticles, reducing their adhesion to mucin fibers [49]. Additionally, the size and shape of MPNs can be optimized to navigate the pores within the mucin network, typically favoring smaller, spherical nanoparticles that can more easily pass through the mucin mesh without becoming trapped [50].

2. Water Content

The high-water content of mucus contributes to its gel-like properties, facilitating the movement of nutrients and waste products while also serving as a barrier to pathogens and drug delivery systems [51]. The hydrophilic nature of PEG and other similar polymers helps MPNs to interact favorably with the aqueous environment of mucus. This interaction is essential for maintaining the mobility of nanoparticles within the mucus layer [52]. By creating a hydration shell around the nanoparticles, PEG and other hydrophilic coatings prevent the aggregation of nanoparticles and ensure that they remain dispersed, thereby enhancing their ability to diffuse through the mucus. Understanding the interplay between MPNs and the water content of mucus is critical for designing nanoparticles that can maintain their functionality in the moist and dynamic environment of mucosal tissues [53].

B. Avoidance of Mucosal Trapping

1. Size and Surface Properties

The size and surface properties of MPNs are critical determinants of their ability to avoid mucosal trapping. Mucus is a selective barrier that can hinder the movement of larger particles while allowing smaller ones to pass through more freely [54]. Nanoparticles in the range of 100-200 nm are typically more effective at penetrating mucus due to their ability to navigate the mucus mesh without becoming entrapped. Surface properties, particularly hydrophilicity and charge, play a significant role in determining the interactions between nanoparticles and mucins [55]. Hydrophilic surfaces, achieved through coatings such as PEG, reduce hydrophobic interactions with mucins. Similarly, neutral or slightly negative surface charges can minimize electrostatic attractions to the negatively charged mucin fibers, further facilitating the movement of MPNs through the mucus [56].

2. Overcoming Adhesive Interactions

Overcoming adhesive interactions between nanoparticles and mucus is essential for ensuring that MPNs can reach their target sites. Various strategies are employed to reduce these interactions, including the use of stealth coatings like PEG, which provide a hydrophilic barrier that prevents adhesion to mucin fibers [57]. Additionally, the surface chemistry of nanoparticles can be tailored to repel mucins. For example, zwitterionic coatings that present both positive and negative charges on their surface can create a net neutral charge, reducing the likelihood of binding to mucins [58]. Another approach involves the use of mucolytic agents that temporarily alter the mucus structure, reducing its viscosity and enhancing the penetration of nanoparticles. These strategies collectively help MPNs to navigate the mucus barrier more effectively, increasing their potential for successful drug delivery [59].

C. Diffusion through the Mucus Layer

1. Experimental Methods to Study Diffusion

To optimize MPN design, it is crucial to understand how these particles diffuse through mucus.

Experimental methods such as multiple particle tracking (MPT) and fluorescence recovery after photobleaching (FRAP) are commonly used to study the diffusion of nanoparticles in mucus [23, 43]. MPT involves tracking the movement of fluorescently labeled nanoparticles within a mucus sample, providing insights into their mobility and interactions with the mucus network [7]. FRAP, on the other hand, measures the time it takes for fluorescently labeled particles to diffuse back into a bleached area, giving an indication of their diffusion coefficients [18, 4]. These methods allow researchers to quantify the extent to which nanoparticles penetrate mucus and identify factors that influence their movement. Understanding these factors is essential for designing nanoparticles with optimal properties for mucus penetration [60].

2. Modeling and Simulation Approaches

In addition to experimental methods, modeling and simulation approaches play a significant role in understanding the diffusion of MPNs through mucus. Computational models can simulate the interactions between nanoparticles and mucus components, providing detailed insights into the dynamics of mucus penetration [14]. These models can incorporate various factors, such as nanoparticle size, surface properties, and the rheological properties of mucus, to predict the behavior of MPNs. Simulations can help identify optimal design parameters for nanoparticles and suggest modifications that could enhance their penetration capabilities [55]. By combining experimental data with computational models, researchers can develop a comprehensive understanding of the mechanisms underlying mucus penetration and design more effective MPNs for drug delivery [61].



Figure 2: Mucus-penetrating nanoparticles for gene delivery

IV. Applications of Mucus-Penetrating Nanoparticles

Mucus-penetrating nanoparticles (MPNs) have demonstrated versatility and efficacy in various routes of administration, offering promising applications across different mucosal surfaces [61].

A. Pulmonary Delivery

1. Treatment of Respiratory Diseases

MPNs show great potential in the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis [19]. By enhancing mucus penetration and improving drug retention in the lungs, MPNs can enhance the efficacy of inhaled therapies. They enable targeted delivery of bronchodilators, corticosteroids, and antibiotics directly to the site of inflammation or infection within the respiratory tract [62].

2. Inhalation Therapies

Inhalation therapies using MPNs offer several advantages, including rapid onset of action, reduced systemic side effects, and improved patient compliance [6]. MPNs can encapsulate both hydrophobic and hydrophilic drugs, ensuring controlled release and prolonged therapeutic effects in the lungs [15]. This makes them particularly valuable for managing chronic respiratory conditions and delivering biologics that would otherwise be degraded in the gastrointestinal tract [63].

B. Gastrointestinal Delivery

1. Oral Drug Delivery Systems

MPNs have revolutionized oral drug delivery by overcoming the challenges posed by the acidic environment of the stomach and the enzymatic degradation in the gastrointestinal tract. They protect drugs from degradation, enhance their absorption through intestinal epithelial cells, and improve bioavailability [17]. MPNs are particularly effective for delivering poorly soluble drugs and sensitive biologics that require protection from enzymatic degradation [64].

2. Treatment of GI Diseases

In the treatment of gastrointestinal (GI) diseases such as inflammatory bowel disease (IBD), MPNs offer targeted delivery of anti-inflammatory agents directly to the inflamed mucosa[18]. By penetrating the mucus layer lining the GI tract, MPNs can deliver drugs to the site of inflammation, reducing systemic exposure and minimizing side effects. This targeted approach improves therapeutic outcomes and patient adherence to treatment regimens [65].

Targeted Tissue/Organs	Transport Through Mucus	Controlled Release Mechanisms	References
Respiratory System	Enhanced penetration due to surface modification	pH-sensitive coatings, polymer matrices	[15]
Gastrointestinal Tract	Adhesion to epithelial surfaces	Layer-by-layer assembly, nanoparticle encapsulation	[44]
Central Nervous System	BBB penetration facilitated by ligand-functionalized particles	Lipid bilayer diffusion, stimuli-responsive polymers	[35]
Cancerous Tissues	Targeting ligands for specific receptors	Nanogels, hydrogel matrices	[46]
Skin and Dermis	Topical application with penetration enhancers	Transdermal patches, microneedles	[24]
Ocular Surface	Enhanced residence time due to mucoadhesive properties	Thermosensitive hydrogels, intraocular implants	[43]
Musculoskeletal System	Joint targeting using specific ligands	Biodegradable microspheres, intra-articular injections	[11]
Reproductive System	Targeting to reproductive organs	Hormonal control, vaginal rings	[19]
Cardiovascular System	Endothelial targeting via ligand-functionalized nanoparticles	Liposomal carriers, stent coatings	[32]
Liver and Hepatic System	Hepatocyte-specific delivery	Galactose ligands, bile acid-conjugated nanoparticles	[23]

C. Genitourinary Delivery

1. Vaginal and Rectal Delivery

MPNs are explored for vaginal and rectal drug delivery, addressing challenges such as rapid clearance and limited drug absorption. In vaginal applications, MPNs can deliver contraceptives, antimicrobials, and hormones directly to the vaginal mucosa, enhancing efficacy and reducing systemic exposure [66]. Similarly, in rectal delivery, MPNs facilitate the absorption of drugs for treating conditions like hemorrhoids and inflammatory bowel diseases [32].

2. Sexual Health and Reproductive Applications

MPNs have implications for sexual health and reproductive medicine, including the delivery of contraceptives, antivirals for sexually transmitted infections (STIs), and fertility treatments [14]. By enhancing drug penetration through the vaginal or rectal mucosa, MPNs offer a promising approach for targeted delivery and sustained release of therapeutics in the genitourinary tract [67].

D. Nasal Delivery

1. Vaccination

Nasal delivery using MPNs has emerged as a promising strategy for vaccination. MPNs can encapsulate antigens and adjuvants, facilitating their transport across the nasal mucosa to induce both mucosal and systemic immune responses [12, 7]. This route of administration offers advantages such as needle-free delivery, improved patient compliance, and enhanced immune response compared to traditional injection-based vaccine [68].

2. CNS Drug Delivery

MPNs hold potential for delivering drugs to the central nervous system (CNS) via the nasal route. The nasal mucosa provides direct access to the brain through the olfactory and trigeminal nerve pathways [25]. MPNs can encapsulate neurotherapeutics, bypassing the blood-brain barrier and delivering drugs to target areas within the CNS [17]. This approach is particularly relevant for treating neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy [69].

V. Advantages of Mucus-Penetrating Nanoparticles

Mucus-penetrating nanoparticles (MPNs) offer several distinct advantages that make them valuable tools in drug delivery systems, particularly for targeting mucosal surfaces[21,70].

A. Enhanced Bioavailability

MPNs enhance the bioavailability of drugs by overcoming the barriers posed by mucus layers at mucosal surfaces. Mucus typically acts as a protective barrier that can hinder drug absorption. MPNs are designed to penetrate through this barrier, facilitating direct contact with underlying epithelial cells and enhancing drug uptake [44, 6]. This improved bioavailability ensures that a higher proportion of the administered drug reaches its target site, thereby improving therapeutic efficacy [71].

B. Prolonged Retention and Sustained Release

One of the key advantages of MPNs is their ability to achieve prolonged retention and sustained release of drugs at mucosal sites [55]. By minimizing rapid clearance through mucus turnover and mucociliary clearance mechanisms, MPNs can extend the residence time of drugs within the mucosal tissues. This prolonged retention allows for sustained release of the encapsulated drug, maintaining therapeutic concentrations over an extended period [15]. Such controlled

release profiles are particularly beneficial for chronic conditions requiring continuous drug delivery or for achieving steady-state drug levels [72, 9].

C. Targeted Delivery to Specific Sites

MPNs enable targeted delivery of drugs to specific mucosal sites, which is critical for treating localized diseases and minimizing off-target effects [40]. Through surface modifications and ligand conjugation, MPNs can be tailored to recognize and bind to receptors or specific cells within mucosal tissues. This targeted approach enhances the accumulation of therapeutic agents at the site of action, improving efficacy while reducing the required dosage and potential systemic toxicity [73].

D. Reduction of Systemic Side Effects

By enhancing localized delivery and reducing systemic exposure, MPNs contribute to minimizing systemic side effects associated with traditional drug delivery methods. Conventional systemic administration routes often result in higher drug concentrations in non-target tissues and organs, leading to adverse effects [74]. MPNs facilitate drug delivery directly to the affected mucosal site, thereby reducing systemic exposure and the likelihood of systemic side effects. This targeted delivery approach enhances the safety profile of drugs and improves patient tolerance to treatments [75].

VI. Challenges and Limitations

Despite their promising applications, mucus-penetrating nanoparticles (MPNs) face several challenges and limitations that must be addressed to realize their full potential in drug delivery systems [76].

A. Biological Barriers and Immune Responses

1. Mucosal Immune System Interactions

MPNs encounter complex interactions with the mucosal immune system, which can influence their efficacy and safety. Mucosal surfaces, such as those in the respiratory, gastrointestinal, and genitourinary tracts, are equipped with specialized immune cells and mechanisms designed to protect against pathogens [77]. The presence of immune cells, including dendritic cells and macrophages, may recognize and respond to nanoparticles, potentially triggering immune reactions or altering nanoparticle behavior [43]. Understanding these interactions is crucial to mitigate immune responses and ensure the delivery of therapeutic payloads [78].

2. Potential Toxicity and Biocompatibility Issues

Another significant concern is the potential toxicity and biocompatibility of MPNs. The materials used in nanoparticle formulations, such as polymers and surface coatings, must be carefully selected to minimize adverse effects on mucosal tissues and systemic circulation [79]. Chronic exposure to nanoparticles could lead to accumulation in organs or tissues, raising safety concerns [54]. Additionally, the interaction of nanoparticles with biological fluids and cells may induce unintended cytotoxicity or inflammatory responses. Comprehensive preclinical studies are essential to assess the biocompatibility and long-term safety profile of MPNs before clinical translation [80].

B. Manufacturing and Scalability

1. Production Challenges

The manufacturing of MPNs poses several challenges related to reproducibility, scalability, and cost-effectiveness [81]. The synthesis of nanoparticles with precise size, shape, and surface properties requires sophisticated manufacturing techniques, such as nanoprecipitation,

emulsion methods, or microfluidics [66]. Achieving batch-to-batch consistency and scaling up production to meet commercial demands remain significant hurdles. Moreover, the choice of raw materials and processing conditions can affect nanoparticle characteristics and performance, necessitating robust manufacturing protocols [82].

2. Quality Control and Standardization

Ensuring quality control and standardization in MPN production is critical for maintaining product efficacy and safety [83]. Variability in nanoparticle size distribution, drug loading efficiency, and stability can impact therapeutic outcomes and regulatory approval [33]. Rigorous analytical methods, such as dynamic light scattering, electron microscopy, and spectroscopic techniques, are employed to characterize nanoparticles and monitor batch-to-batch consistency. Establishing standardized protocols and quality assurance measures is essential to meet regulatory requirements and ensure patient safety [84].

VII. Future Directions and Perspectives

The future of mucus-penetrating nanoparticles (MPNs) holds exciting prospects for advancing drug delivery capabilities and personalized medicine [85].

A. Emerging Technologies and Innovations

1. Advanced Materials and Fabrication Techniques

Future advancements in MPNs will likely focus on integrating advanced materials and refining fabrication techniques. Novel polymers with tailored physicochemical properties, such as biodegradability and stimuli-responsive behavior, will enhance the functionality and safety of MPNs [86]. Advanced fabrication methods, including 3D printing and microfluidics, offer precise control over nanoparticle size, shape, and surface characteristics, optimizing their mucus-penetrating abilities [12]. Furthermore, the incorporation of nanotechnology-enabled drug delivery systems, such as nanogels and nanocrystals, promises to expand the therapeutic potential of MPNs across diverse medical applications [87].

2. Multifunctional Nanoparticles

The development of multifunctional MPNs represents a transformative direction in drug delivery. These nanoparticles are engineered to possess multiple functionalities, such as simultaneous drug delivery, imaging capabilities, and therapeutic targeting [88]. By integrating targeting ligands, imaging agents (e.g., fluorescent dyes or contrast agents), and stimuli-responsive components (e.g., pH or temperature-sensitive polymers), multifunctional MPNs enable real-time monitoring of drug release and therapeutic response [89]. This multifaceted approach enhances treatment efficacy, facilitates personalized medicine, and supports theranostic applications where diagnosis and therapy are integrated into a single platform [90].

B. Personalized Medicine Approaches

1. Patient-Specific Formulations

The advent of personalized medicine is driving the development of MPNs tailored to individual patient characteristics and therapeutic needs [5]. Advances in genomics, proteomics, and biomarker identification enable the customization of drug formulations based on genetic profiles, disease phenotypes, and drug metabolism pathways [91]. Nanoparticle-based drug delivery systems can be engineered to deliver precise doses of therapeutics to specific target sites within mucosal tissues, optimizing treatment outcomes while minimizing adverse effects. Personalized MPNs hold promise for treating complex diseases with varying patient responses, fostering a shift towards precision medicine in clinical practice [92].

2. Precision Targeting

Precision targeting strategies aim to enhance the specificity and efficacy of MPNs in delivering therapeutics to diseased tissues or cells [93]. By leveraging surface modifications and targeting ligands, MPNs can selectively bind to receptors or biomarkers overexpressed in diseased tissues, such as cancer cells or inflamed mucosa [94]. This targeted approach improves drug accumulation at the site of action, maximizing therapeutic efficacy while reducing systemic exposure and off-target effects [95]. Advances in nanotechnology and molecular biology will continue to refine precision targeting strategies, paving the way for enhanced therapeutic outcomes and improved patient care in personalized medicine [96, 97].

Conclusion

Mucus-penetrating nanoparticles (MPNs) represent a transformative innovation in drug delivery, offering solutions to overcome the formidable barriers presented by mucosal tissues. Their ability to enhance bioavailability, achieve sustained release, and enable targeted delivery to specific sites holds tremendous promise across various medical applications. Despite the challenges of biological interactions, manufacturing complexities, and regulatory hurdles, ongoing advancements in advanced materials, fabrication techniques, and multifunctional designs are propelling MPNs towards broader clinical adoption. The future of MPNs lies in their integration with personalized medicine approaches, where patient-specific formulations and precision targeting strategies promise to revolutionize therapeutic outcomes. By harnessing nanotechnology and leveraging insights from biomolecular sciences, MPNs are poised to address unmet medical needs, ranging from respiratory diseases and gastrointestinal disorders to genitourinary and neurological conditions. Collaborative efforts between researchers, clinicians, and regulatory bodies will be crucial in translating these innovations into clinically viable therapies. As MPNs continue to evolve, their potential to improve treatment efficacy, reduce systemic side effects, and enable tailored therapeutic interventions underscores their pivotal role in shaping the future of mucosal drug delivery and personalized medicine.

References

1. J.A. MacKay, D.F. Deen, and J.F.C. Szoka, "Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating," Brain Res., 2005, vol. 1035, pp. 139–153.
2. S.K. Lai et al., "Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway," Biomaterials, 2007.
3. L.K. Medina-Kauwe, J. Xie, and S. Hamm-Alvarez, "Intracellular trafficking of nonviral vectors," Gene Ther., 2005, vol. 12, pp. 1734–1751.
4. E. Allemann, J.C. Leroux, and R. Gurny, "Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics," Adv. Drug Deliv. Rev., 1998, vol. 34, pp. 171–189.
5. J. Panyam and V. Labhasetwar, "Biodegradable nanoparticles for drug and gene delivery to cells and tissue," Adv. Drug Deliv. Rev., 2003, vol. 55, pp. 329–347.
6. M.R. Knowles and R.C. Boucher, "Mucus clearance as a primary innate defense mechanism for mammalian airways," J. Clin. Invest., 2002, vol. 109, pp. 571–577.
7. R. Cone, "Mucus," in Mucosal Immunology, M. W. Lamm, E. McGhee, J. R. Mayer, L. B. Mestecky, and J. Bienenstock, Eds. San Diego: Academic Press, 1999, pp. 43–64.
8. R. Cone, "Barrier Properties of Mucus," Adv. Drug Deliv. Rev., 2008, Accepted.
9. M.A. Sleigh, J.R. Blake, and N. Liron, "The propulsion of mucus by cilia," Am. Rev. Respir. Dis., 1988, vol. 137, pp. 726–741.
10. J. Widdicombe, "Airway surface liquid: concepts and measurements," in Airway Mucus:

Basic Mechanisms and Clinical Perspectives, D.R. Lethem, Ed. Boston, MA: Birkhauser, 1997, pp. 1–18.

11. J. Ally, A. Amirfazli, and W. Roa, "Model studies of magnetic particle retention in the conducting airways," in Proceedings of the 2005 International Conference on MEMS, NANO and Smart Systems, 2005.
12. J. Overton and F. Miller, "Dosimetry Modeling of Inhaled Toxic Reactive Gases," in Air Pollution, the Automobile, and Public Health, R.B. Watson and D. Kennedy, Eds. Washington, DC: The National Academies Press, 1988.
13. M.T. Clunes and R.C. Boucher, "Cystic Fibrosis: The Mechanisms of Pathogenesis of an Inherited Lung Disorder," Drug Discov. Today Dis. Mech., 2007, vol. 4, pp. 63–72.
14. H. Matsui et al., "Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease," Cell, 1998, vol. 95, pp. 1005–1015.
15. R. Tarran et al., "The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition," J. Gen. Physiol., 2001, vol. 118, pp. 223–236.
16. A.S. Verkman, Y. Song, and J.R. Thiagarajah, "Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease," Am. J. Physiol. Cell Physiol., 2003, vol. 284, pp. C2–15.
17. Behrens, P. Stenberg, P. Artursson, and T. Kissel, "Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells," Pharm. Res., 2001, vol. 18, pp. 1138–1145.
18. M. Copeman et al., "The gastroduodenal mucus barrier and its role in protection against luminal pepsins: the effect of 16,16 dimethyl prostaglandin E2, carbopol-polyacrylate, sucralfate and bismuth subsalicylate," J. Gastroenterol. Hepatol., 1994, vol. 9, Suppl 1, pp. S55–59.
19. F.J. Holly and M.A. Lemp, "Tear physiology and dry eyes," Surv Ophthalmol., vol. 22, pp. 69–87, 1977.
20. P.E. King-Smith, B.A. Fink, R.M. Hill, K.W. Koelling, and J.M. Tiffany, "The thickness of the tear film," Curr Eye Res., vol. 29, pp. 357–368, 2004.
21. J.I. Prydal, P. Artal, H. Woon, and F.W. Campbell, "Study of human precorneal tear film thickness and structure using laser interferometry," Invest Ophthalmol Vis Sci., vol. 33, pp. 2006–2011, 1992.
22. R.M. Mainardes, M.C. Urban, P.O. Cinto, M.V. Chaud, R.C. Evangelista, and M.P. Gremiao, "Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery," Curr Drug Deliv., vol. 3, pp. 275–285, 2006.
23. K. Saketkhoo, A. Januszkiewicz, and M.A. Sackner, "Effects of drinking hot water, cold water, and chicken soup on nasal mucus velocity and nasal airflow resistance," Chest, vol. 74, pp. 408–410, 1978.
24. S.A. Galindo-Rodriguez, E. Allemann, H. Fessi, and E. Doelker, "Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies," Crit Rev Ther Drug Carrier Syst., vol. 22, pp. 419–464, 2005.
25. C.M. Lehr, F.G.J. Poelma, H.E. Junginger, and J.J. Tukker, "An Estimate of Turnover Time of Intestinal Mucus Gel Layer in the Rat Insitu Loop," Int J Pharm., vol. 70, pp. 235–240, 1991.
26. S.L. Kieweg, A.R. Geonnotti, and D.F. Katz, "Gravity-induced coating flows of vaginal gel formulations: in vitro experimental analysis," J Pharm Sci., vol. 93, pp. 2941–2952, 2004.
27. S.L. Kieweg and D.F. Katz, "Squeezing flows of vaginal gel formulations relevant to microbicide drug delivery," J Biomech Eng., vol. 128, pp. 540–553, 2006.

28. J.T. Lamont, "Mucus: the front line of intestinal mucosal defense," Ann N Y Acad Sci., vol. 664, pp. 190–201, 1992.
29. W.M. Saltzman, M.L. Radomsky, K.J. Whaley, and R.A. Cone, "Antibody Diffusion in Human Cervical-Mucus," Biophys J., vol. 66, pp. 508–515, 1994.
30. B. Amsden, "Solute diffusion within hydrogels. Mechanisms and models," Macromolecules, vol. 31, pp. 8382–8395, 1998.
31. B. Amsden, "An obstruction-scaling model for diffusion in homogeneous hydrogels," Macromolecules, vol. 32, pp. 874–879, 1999.
32. J. Hanes, M. Dawson, Y. Har-el, J. Suh, and J. Fiegel, "In: Gene Delivery to the Lung, Pharmaceutical Inhalation Aerosol Technology," in Hickey AJ, Ed. Marcel Dekker Inc.; New York, 2003, pp. 489–539.
33. D.A. Norris and P.J. Sinko, "Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin," J App Polym Sci., vol. 63, pp. 1481–1492, 1997.
34. J.K. Sheehan, K. Oates, and I. Carlstedt, "Electron microscopy of cervical, gastric and bronchial mucus glycoproteins," Biochem J., vol. 239, pp. 147–153, 1986.
35. B. Drumm, A.W. Neumann, Z. Policova, and P.M. Sherman, "Bacterial cell surface hydrophobicity properties in the mediation of in vitro adhesion by the rabbit enteric pathogen Escherichia coli strain RDEC-1," J Clin Invest., vol. 84, pp. 1588–1594, 1989.
36. Dharmendra Bhati et al., “FUSED AND SUBSTITUTED PYRIMIDINE DERIVATIVES AS POTENT ANTICANCER AGENTS,” Biochemical and Cellular Archives/Bio chemical and cellular archives, vol. 24, no. 1, Jan. 2024, doi: https://doi.o rg/10.5147 0/bca.2024.24.1.749.
37. K. J. Mangala et al., “NANOCELLULOSE: A VERSATILE AND SUSTAINABLE CARRIER FOR DRUG AND BIOACTIVE COMPOUNDS,” Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.553.
38. Rohit Kumar Trivedi et al., “REVOLUTIONIZING DRUG DELIVERY THROUGH 3D PRINTING TECHNOLOGY: CURRENT ADVANCES AND FUTURE DIRECTIONS,” Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.521.
39. H. Rastogi, P. Bhatt, S. Garg, S. Kamboj, V. Deva, and R. Goel, “EXPLORING THE POTENTIAL OF QUANTUM DOTS AS LUMINOUS PROBES FOR TARGETED DRUG DELIVERY AND BIOIMAGING IN CLINICAL DIAGNOSTICS,” Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 24, no. 1, Jan. 2024, doi: https://doi.org/10.51470/bca.2024.24.1.457.
40. M. shama, “CRISPR-Cas9 gene editing in pharmaceuticals: Current applications and future prospects,” Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 23, no. S1, Dec. 2023, doi: https://doi.org/10.51470/bca.2023.23.s1.1655.
41. S. Arora, Saiphali, G. Dharmamoorthy Dharmendra Bhati, T. Gupta, and P. Bhatt, “Advancements in peptide-based therapeutics: Design, synthesis and clinical applications,” Biochemical and Cellular Archives/Biochemical and cellular archives, vol. 23, no. S1, Dec. 2023, doi: https://doi.org/10.51470/bca.2023.23.s1.1415.
42. M. Singhal et al., "Formulation development and characterization of powder for oral suspension containing H2 blocker drug to combat GERD and peptic ulcer," NeuroQuantology, vol. 20, no. 11, pp. 1258, 2022.
43. S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE, 2022.

44. V. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," International Journal of Pharmaceutical Sciences and Research, vol. 11, no. 5, pp. 2193–2198, 2020.
45. A. E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," GSC biol pharm sci, vol. 19, no. 3, pp. 148–155, 2022.
46. B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., Encyclopedia of green materials. Singapore: Springer Nature Singapore, 2022.
47. P. Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy- A review," Am J PharmTech Res, vol. 9, no. 3, pp. 321–331, 2019.
48. P. Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in The Flavonoids, 2024, pp. 131-152.
49. P. Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloa esculenta) starch," ACS Omega, vol. 8, no. 33, pp. 30294–305, 2023.
50. P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," Pharmaceutics, vol. 15, no. 8, p. 2066, 2023.
51. P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," Pharma Science Monitor, vol. 9, no. 2, 2018.
52. P. Bhatt et al., "Development and characterization of fast dissolving buccal strip of frovatriptan succinate monohydrate for buccal delivery," Int J Pharm Investig, vol. 11, no. 1, pp. 69–75, 2021.
53. P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," The Chinese Journal of Artificial Intelligence, 2023.
54. P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in Blockchain for Healthcare Systems, 2021, pp. 97–113.
55. P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium–A Review," World J. Pharm. Pharm. Sci, vol. 7, no. 9, pp. 271-287, 2018.
56. C. Goyal et al., "Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents," Res J Pharm Technol, pp. 5078–5083, 2022.
57. T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," J Pharm Res Int, pp. 70–78, 2021.
58. M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin," Phytomed Plus, vol. 3, no. 2, p. 100445, 2023.
59. A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," J Chem Pharm Sci, vol. 12, no. 03, pp. 71–78, 2019.
60. M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," Nat Prod J, 2022.
61. M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice," ACS Omega, vol. 7, no. 40, pp. 35506–35514, 2022.
62. M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," ACS Omega, vol. 8, no. 13, pp. 11750–11767, 2023.
63. Pankaj, "Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy," J Pharm Res Int, pp. 54–63, 2021.
64. Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," J Pharm Res Int,

pp. 21–29, 2021.
65. V. Raghuwanshi et al., "Recent Advances In Nanotechnology For Combating Against Corona Virus Infection," Journal of Pharmaceutical Negative Results, pp. 1811-1820, 2022.
66. K. K. Sahu et al., "Utility of nanomaterials in wound management," in Nanotechnological Aspects for Next-Generation Wound Management, 2024, pp. 101–130.
67. S. K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," J Infect Public Health, vol. 15, no. 5, pp. 566–572, 2022.
68. S. K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," J Pharm Res Int, pp. 5–13, 2021.
69. S. K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," Journal of Pharmaceutical Research International, vol. 32, no. 36, pp. 82-88, 2022.
70. S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," WJPMR, vol. 8, no. 4, pp. 216–225, 2022.
71. S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits," in Advances in Flavonoids for Human Health and Prevention of Diseases, 2024, pp. 23-46.
72. S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in Blockchain for Healthcare Systems, 2021, pp. 61–79.
73. S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," Journal of Pharmaceutical Negative Results, pp. 1463-1469, 2022.
74. R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and Development," in 2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART), 2023, pp. 556-561.
75. P. Bhatt et al., “Impact of Cross-Linking on the Physicochemical and Physiological Characteristics of Barnyard Millet (Echinochloa frumentacea) Grains Starch,” Stärke/Starch, May 2024, doi: https://doi.org/10.1002/star.202300285.
76. V. Kumar et al., “Ultrasound assisted techniques for starch modification to develop novel drug delivery systems: A comprehensive study,” Journal of bioactive and compatible polymers, May 2024, doi: https://doi.org/10.1177/08839115241249143.
77. C. Wickstrom et al., "MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage," Biochem. J., 1998, vol. 334, pp. 685–693.
78. J. Sheehan and I. Carlstedt, "Hydrodynamic properties of human cervical-mucus glycoproteins in 6M-guanidinium chloride," Biochem. J., 1984, vol. 217, pp. 93–101.
79. D.J. Thornton, D.F. Holmes, J.K. Sheehan, and I. Carlstedt, "Quantitation of mucus glycoproteins blotted onto nitrocellulose membranes," Anal. Biochem., 1989, vol. 182, pp. 160–164.
80. J. Dekker, J.W.A. Rossen, H.A. Buller, and A.W.C. Einerhand, "The MUC family: an obituary," Trends Biochem. Sci., 2002, vol. 27, pp. 126–131.
81. M.S. Ali and J.P. Pearson, "Upper airway mucin gene expression: a review," Laryngoscope, 2007, vol. 117, pp. 932–938.
82. B.K. Rubin, "Physiology of airway mucus clearance," Respir. Care, 2002, vol. 47, pp. 761–768.
83. A.P. Corfield, D. Carroll, N. Myerscough, and C.S. Probert, "Mucins in the gastrointestinal tract in health and disease," Front. Biosci, 2001, vol. 6, pp. D1321–1357.
84. I.K. Gipson, "Mucins of the human endocervix," Front. Biosci, 2001, vol. 6, pp. D1245–1255.
85. D.J. Thornton, I. Carlstedt, M. Howard, P.L. Devine, M.R. Price, and J.K. Sheehan,

"Respiratory mucins: identification of core proteins and glycoforms," Biochem. J., 1996, vol. 316, pp. 967–975.

86. B.J. Van Klinken, J. Dekker, H.A. Buller, and A.W. Einerhand, "Mucin gene structure and expression: protection vs. adhesion," Am. J. Physiol., 1995, vol. 269, pp. G613–627.
87. H.S. Slayter, J.K. Wold, and T. Midtvedt, "Intestinal mucin of germ-free rats. Biochemical and electron-microscopic characterization," Carbohydr. Res., 1991, vol. 222, pp. 1–9.
88. E.C. Yurewicz, F. Matsuura, and K.S. Moghissi, "Structural studies of sialylated oligosaccharides of human midcycle cervical mucin," J. Biol. Chem., 1987, vol. 262, pp. 4733–4739.
89. Allen, G. Flemstrom, A. Garner, and E. Kivilaakso, "Gastroduodenal mucosal protection," Physiol. Rev., 1993, vol. 73, pp. 823–857.
90. Carlstedt, H. Lindgren, J.K. Sheehan, U. Ulmsten, and L. Wingerup, "Isolation and characterization of human cervical-mucus glycoproteins," Biochem. J., 1983, vol. 211, pp. 13–22.
91. C.C.W. Chao, S.M. Butala, and A. Herp, "Studies on the isolation and composition of human ocular mucin," Exp. Eye Res., 1988, vol. 47, pp. 185–196.
92. S.S. Hehar et al., "Twenty-four hour ambulatory nasal pH monitoring," Clin. Otolaryngol. Allied Sci., 1999, vol. 24, pp. 24–25.
93. S.J. Jackson et al., "Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na (+)] and pH but elevated viscosity," Proc. Natl. Acad. Sci. U.S.A., 2001, vol. 98, pp. 8119–8123.
94. J.L. Greaves and C.G. Wilson, "Treatment of diseases of the eye with mucoadhesive delivery systems," Adv. Drug Deliv. Rev., 1993, vol. 11, pp. 349–383.
95. S. Schreiber and P. Scheid, "Gastric mucus of the guinea pig: proton carrier and diffusion barrier," Am. J. Physiol., 1997, vol. 272, pp. G63–70.
96. E.R. Boskey et al., "Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source," Hum. Reprod, 2001, vol. 16, pp. 1809–1813.
97. C. Valenta, "The use of mucoadhesive polymers in vaginal delivery," Adv. Drug Deliv. Rev., 2005, vol. 57, pp. 1692–1712.